North American silent heart attack market is estimated to grow significantly at a CAGR of around 6.8% during the forecast period. North America contributes the major share in the global silent heart attack treatment market, owing to the rising heart patients, increase in FDA approvals, and favorable government policies for healthcare sector. Moreover, the rising adoption of minimally invasive/non-invasive surgeries and advancement in treatment technology is anticipated to further drive the growth of the market in the region. According to WHO, factors such as diabetes, hypertension and obesity are also responsible for rising heart diseases in North America as these factors increases the risk of heart related problems. North America has a considerable market share of cardiovascular stents, catheters, rhythm management and other devices that are used in the treatment of silent heart attack. Moreover, the high cost of drugs and procedures in the US and the significant sale of branded drugs in the region are other factors contributing into the growth of the market.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/north-american-silent-heart-attack-market
North American silent heart attack market is segmented into diagnosis, treatment, and end-user. Based on the diagnosis, the market is segmented into an electrocardiography (ECG), chest x-ray, computed tomography (CT Scan), echocardiography, and others (blood test). Based on treatment, the market is segmented into medication and surgery. Based on end-user, the market is segmented into hospitals & clinics and ambulatory surgical centers (ASCs). ECG is the most used technology to diagnose silent heart attack. ECG provides insights about heart rate, indicates, if there is enlargement of the heart due to high blood pressure (hypertension) or evidence of a previous heart attack.
The companies which are contributing to the growth of the North American silent heart attack market include Abbott Laboratories Inc., Johnson & Johnson Services Inc., Pfizer Inc., Bayer AG, and Novartis AG. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.
North American Silent Heart Attack Market Segmentation
By Diagnosis
- Electrocardiography (ECG)
- Magnetic Resonance Imaging (MRI)
- Computed Tomography (CT Scan)
- Echocardiography
- Others (Blood Test)
By Treatment
- Medication
- Surgery
- Angioplasty
- Bypass Surgery
- Heart Transplant
By End-Users
- Hospital & Clinics
- Ambulatory Surgical Centers
A full report of North American Silent heart attack Market available @ https://www.omrglobal.com/industry-reports/north-american-silent-heart-attack-market
North American Silent Heart Attack Market Regional Analysis
- United States
- Canada
